HUP0102322A2 - Fehérje farnezil-transzferáz és HMG-CoA reduktáz inhibitorok kombinációi és alkalmazásuk rák kezelésére - Google Patents
Fehérje farnezil-transzferáz és HMG-CoA reduktáz inhibitorok kombinációi és alkalmazásuk rák kezeléséreInfo
- Publication number
- HUP0102322A2 HUP0102322A2 HU0102322A HUP0102322A HUP0102322A2 HU P0102322 A2 HUP0102322 A2 HU P0102322A2 HU 0102322 A HU0102322 A HU 0102322A HU P0102322 A HUP0102322 A HU P0102322A HU P0102322 A2 HUP0102322 A2 HU P0102322A2
- Authority
- HU
- Hungary
- Prior art keywords
- combinations
- coa reductase
- reductase inhibitors
- treat cancer
- hmg coa
- Prior art date
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title 1
- 108010054353 p21(ras) farnesyl-protein transferase Proteins 0.000 title 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 title 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 102000007317 Farnesyltranstransferase Human genes 0.000 abstract 1
- 108010007508 Farnesyltranstransferase Proteins 0.000 abstract 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 abstract 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
57) A jelen találmány olyan vegyületek kombinációjára vonatkozik,amelyek felhasználhatók a gyógyászat területén humán szövetekszabályozatlan vagy abnormális proliferációjának kezelésére,profilaktikusan vagy más módon. Közelebbről, a jelen találmány aprotein farnezil-transzferázt (PFT) gátló vegyületek és a HMG-CoAreduktázt gátló vegyületek kombinációira vonatkozik. Ó
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8520298P | 1998-05-12 | 1998-05-12 | |
US9225398P | 1998-07-10 | 1998-07-10 | |
PCT/US1999/010188 WO1999058505A2 (en) | 1998-05-12 | 1999-05-10 | Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0102322A2 true HUP0102322A2 (hu) | 2001-11-28 |
HUP0102322A3 HUP0102322A3 (en) | 2001-12-28 |
Family
ID=26772425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0102322A HUP0102322A3 (en) | 1998-05-12 | 1999-05-10 | Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer |
Country Status (26)
Country | Link |
---|---|
US (1) | US6492410B1 (hu) |
EP (1) | EP1077949A2 (hu) |
JP (1) | JP2002514628A (hu) |
KR (1) | KR20010043529A (hu) |
CN (1) | CN1171874C (hu) |
AP (1) | AP2000001984A0 (hu) |
AU (1) | AU758891B2 (hu) |
BG (1) | BG105003A (hu) |
BR (1) | BR9911785A (hu) |
CA (1) | CA2331295A1 (hu) |
EA (1) | EA003860B1 (hu) |
EE (1) | EE200000660A (hu) |
GE (1) | GEP20032996B (hu) |
HK (1) | HK1038355A1 (hu) |
HR (1) | HRP20000771A2 (hu) |
HU (1) | HUP0102322A3 (hu) |
ID (1) | ID27933A (hu) |
IL (1) | IL139502A0 (hu) |
IS (1) | IS5713A (hu) |
NO (1) | NO20005680L (hu) |
NZ (1) | NZ508357A (hu) |
OA (1) | OA11551A (hu) |
PL (1) | PL344662A1 (hu) |
SK (1) | SK16742000A3 (hu) |
WO (1) | WO1999058505A2 (hu) |
YU (1) | YU68900A (hu) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000047196A2 (en) * | 1999-02-11 | 2000-08-17 | Hollis-Eden Pharmaceuticals, Inc. | Use of statins for treating viral infections |
US6455734B1 (en) * | 2000-08-09 | 2002-09-24 | Magnesium Diagnostics, Inc. | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
US20020010128A1 (en) * | 2000-04-13 | 2002-01-24 | Parks Thomas P. | Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism |
US20020132781A1 (en) * | 2000-10-06 | 2002-09-19 | George Kindness | Combination and method of treatment of cancer utilizing a COX-2 inhibitor and A 3-hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA) reductase inhibitor |
GB0220885D0 (en) * | 2002-09-09 | 2002-10-16 | Novartis Ag | Organic compounds |
WO2005042710A1 (en) * | 2003-10-28 | 2005-05-12 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of statin to kill ebv-transformed b cells |
SG166829A1 (en) * | 2005-11-08 | 2010-12-29 | Ranbaxy Lab Ltd | Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
KR100930365B1 (ko) * | 2006-11-09 | 2009-12-08 | 덕성여자대학교 산학협력단 | 심바스타틴을 유효성분으로 함유하는 유방암 치료용 약학적조성물 |
US20080119444A1 (en) * | 2006-11-16 | 2008-05-22 | Steven Lehrer | Methods and compositions for the treatment of cancer |
US10722465B1 (en) | 2017-12-08 | 2020-07-28 | Quicksilber Scientific, Inc. | Transparent colloidal vitamin supplement |
US11344497B1 (en) | 2017-12-08 | 2022-05-31 | Quicksilver Scientific, Inc. | Mitochondrial performance enhancement nanoemulsion |
US11291702B1 (en) | 2019-04-15 | 2022-04-05 | Quicksilver Scientific, Inc. | Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK523288A (da) * | 1987-10-06 | 1989-04-07 | Hoffmann La Roche | Aminosyrederivater |
NL9002031A (nl) | 1990-09-14 | 1992-04-01 | Voskuilen Woudenberg Bv | Inrichting voor het bewerken van een uitwendig buisoppervlak. |
US5571792A (en) | 1994-06-30 | 1996-11-05 | Warner-Lambert Company | Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase |
WO1997000894A1 (en) * | 1995-06-22 | 1997-01-09 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
DK0833847T3 (da) | 1995-06-22 | 2003-12-29 | Biogen Inc | Krystaller af fregmenter af CD40-ligand og deres anvendelse |
UA57081C2 (uk) * | 1997-06-16 | 2003-06-16 | Пфайзер Продактс Інк. | Фармацевтична композиція для лікування раку або доброякісних проліферативних хвороб у ссавців, спосіб лікування, фармацевтична композиція для інгібування ненормального росту клітин у ссавців та спосіб інгібування |
-
1999
- 1999-05-10 EE EEP200000660A patent/EE200000660A/xx unknown
- 1999-05-10 IL IL13950299A patent/IL139502A0/xx unknown
- 1999-05-10 ID IDW20002583A patent/ID27933A/id unknown
- 1999-05-10 GE GEAP19995670A patent/GEP20032996B/en unknown
- 1999-05-10 JP JP2000548309A patent/JP2002514628A/ja active Pending
- 1999-05-10 WO PCT/US1999/010188 patent/WO1999058505A2/en not_active Application Discontinuation
- 1999-05-10 YU YU68900A patent/YU68900A/sh unknown
- 1999-05-10 CN CNB99807649XA patent/CN1171874C/zh not_active Expired - Fee Related
- 1999-05-10 EP EP99922898A patent/EP1077949A2/en not_active Withdrawn
- 1999-05-10 EA EA200001164A patent/EA003860B1/ru not_active IP Right Cessation
- 1999-05-10 AP APAP/P/2000/001984A patent/AP2000001984A0/en unknown
- 1999-05-10 US US09/674,818 patent/US6492410B1/en not_active Expired - Fee Related
- 1999-05-10 KR KR1020007012632A patent/KR20010043529A/ko not_active Application Discontinuation
- 1999-05-10 PL PL99344662A patent/PL344662A1/xx not_active Application Discontinuation
- 1999-05-10 SK SK1674-2000A patent/SK16742000A3/sk unknown
- 1999-05-10 OA OA1200000310A patent/OA11551A/en unknown
- 1999-05-10 BR BR9911785-1A patent/BR9911785A/pt not_active IP Right Cessation
- 1999-05-10 NZ NZ508357A patent/NZ508357A/xx unknown
- 1999-05-10 CA CA002331295A patent/CA2331295A1/en not_active Abandoned
- 1999-05-10 HU HU0102322A patent/HUP0102322A3/hu unknown
- 1999-05-10 AU AU39792/99A patent/AU758891B2/en not_active Ceased
-
2000
- 2000-11-10 IS IS5713A patent/IS5713A/is unknown
- 2000-11-10 NO NO20005680A patent/NO20005680L/no not_active Application Discontinuation
- 2000-11-13 HR HR20000771A patent/HRP20000771A2/hr not_active Application Discontinuation
- 2000-11-29 BG BG105003A patent/BG105003A/xx unknown
-
2001
- 2001-12-27 HK HK01109123A patent/HK1038355A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ID27933A (id) | 2001-05-03 |
CA2331295A1 (en) | 1999-11-18 |
EA200001164A1 (ru) | 2001-06-25 |
EP1077949A2 (en) | 2001-02-28 |
YU68900A (sh) | 2002-12-10 |
AP2000001984A0 (en) | 2000-12-31 |
EE200000660A (et) | 2002-04-15 |
IL139502A0 (en) | 2001-11-25 |
NZ508357A (en) | 2002-09-27 |
IS5713A (is) | 2000-11-10 |
PL344662A1 (en) | 2001-11-19 |
US6492410B1 (en) | 2002-12-10 |
BG105003A (en) | 2001-07-31 |
HUP0102322A3 (en) | 2001-12-28 |
JP2002514628A (ja) | 2002-05-21 |
HRP20000771A2 (en) | 2001-06-30 |
SK16742000A3 (sk) | 2001-07-10 |
CN1306515A (zh) | 2001-08-01 |
AU758891B2 (en) | 2003-04-03 |
HK1038355A1 (en) | 2002-03-15 |
AU3979299A (en) | 1999-11-29 |
GEP20032996B (en) | 2003-06-25 |
EA003860B1 (ru) | 2003-10-30 |
NO20005680D0 (no) | 2000-11-10 |
WO1999058505A3 (en) | 2000-01-06 |
OA11551A (en) | 2004-05-24 |
NO20005680L (no) | 2001-01-10 |
CN1171874C (zh) | 2004-10-20 |
BR9911785A (pt) | 2001-04-03 |
KR20010043529A (ko) | 2001-05-25 |
WO1999058505A2 (en) | 1999-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1562897A4 (en) | PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER | |
WO2003032916A3 (en) | Organosulfur inhibitors of tyrosine phosphatases | |
GB0223040D0 (en) | Therapeutic compounds | |
ATE316785T1 (de) | Jak-3 hemmer zur behandlung von allergischen störungen | |
GB0108770D0 (en) | Inhibitors | |
WO2002074337A8 (en) | Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases | |
WO2003074550A3 (en) | Pin1-modulating compounds and methods of use thereof | |
PT1509232E (pt) | Uma combinação de um antagonista de nmda e inibidores da acetilcolina esterase para o tratamento da doença de alzheimer | |
WO2005004803A3 (en) | Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease | |
AU6257798A (en) | Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase | |
PL362477A1 (en) | Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases | |
MA27556A1 (fr) | Derives de phenylalanine comme inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete | |
MXPA04003668A (es) | Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos. | |
HUP0102322A2 (hu) | Fehérje farnezil-transzferáz és HMG-CoA reduktáz inhibitorok kombinációi és alkalmazásuk rák kezelésére | |
MXPA02002118A (es) | Composiciones que contienen productos leguminosos. | |
WO2000061167A3 (en) | TREATMENT OF MYELOMA BONE DISEASE WITH PROTEASOMAL AND NF-λB ACTIVITY INHIBITORS | |
IL110943A (en) | Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders | |
AU2002248319A1 (en) | Pharmaceutical composition for the prevention and treatment of scar tissue | |
WO2003088748A8 (en) | Use of heme oxygenase-1 and products of heme degradation | |
HUP0301991A2 (hu) | IL-18-inhibitorok alkalmazása atheroszklerózis kezelésére és/vagy megelżzésére | |
AU2002367172A1 (en) | 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents | |
MXPA02002119A (es) | Productos leguminosos. | |
CY1109995T1 (el) | Συνθεσεις περιεχουσες προϊοντα σογιας | |
MXPA02002117A (es) | Uso de productos leguminosos para el tratamiento de agresiones externas. | |
MXPA05009986A (es) | Tratamiento de la enfermedad de alzheimer. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |